What should I look for in LL-37 sourcing and quality?

Acceptable LL-37 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 4493 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How should LL-37 be stored and reconstituted?

Lyophilised LL-37 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What is the standard dosing protocol for LL-37?

Conventional LL-37 dosing is 100-500 mcg daily subq for 4-8 weeks via subq/topical/nebulised. For metabolic and glycemic use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does LL-37's half-life affect dosing?

LL-37 has a plasma half-life of Variable; tissue-localised, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under daily subq for 4-8 weeks dosing at 100-500 mcg per dose explains the typical onset timeline for metabolic and glycemic endpoints.

What are the safety considerations for LL-37?

Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. For metabolic and glycemic use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. LL-37's Variable; tissue-localised pharmacokinetic profile and subq/topical/nebulised administration route influence the side-effect profile in predictable ways.

What class of compound is LL-37?

LL-37 is classified as a Cathelicidin antimicrobial peptide. Within this class, alternative names and analogues include Cathelicidin LL-37, Human cationic antimicrobial protein 18. The class-level pharmacology shapes both the clinical applications and the safety profile; the metabolic / endocrine literature treats LL-37 alongside its class peers when evaluating relative merits.

Home/ Compounds/ LL-37

LL-37

Metabolic

Endocrine and metabolic applications of LL-37 span direct incretin-axis engagement, AMPK and mitochondrial signalling, and adiposity-driven inflammation. The body's principal endogenous antimicrobial peptide — broad-spectrum activity against bacteria, fungi, viruses, and biofilms, plus immunomodulatory effects. The Variable; tissue-localised pharmacokinetic profile and subq/topical/nebulised administration shape the rate at which glycemic markers move; the typical LL-37 effect window in metabolic syndrome populations is 8-12 weeks.

Metabolic / Endocrine Applications

Glucose RegulationGastric EmptyingType 2 Diabetes ResearchCardiometabolic RiskGLP-1 Synergy

Key Takeaways

Metabolic lens: LL-37 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 100-500 mcg daily subq for 4-8 weeks via subq/topical/nebulised.
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. The metabolic medicine framework evaluates LL-37 against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.

Weight management and the appetite circuit

Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.

Insulin signalling and glycemic effect

LL-37's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

AMPK and mitochondrial signalling

Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. LL-37 engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.

Metabolic / Endocrine Applications

Cardiometabolic Risk

Where LL-37 is used for cardiometabolic risk, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Insulin Sensitivity

In the metabolic syndrome population, LL-37 for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Mitochondrial Biogenesis

LL-37 for mitochondrial biogenesis is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Gastric Emptying

Where LL-37 is used for gastric emptying, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Metabolic focus	SubQ	100-500 mcg	Daily SubQ for 4-8 weeks
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for LL-37 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

LL-37 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

LL-37 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with LL-37's mechanism in metabolic / endocrine protocols.
LL-37 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with LL-37's mechanism in metabolic / endocrine protocols.
LL-37 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with LL-37's mechanism in metabolic / endocrine protocols.
LL-37 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with LL-37's mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions.

Lens-specific safety considerations for metabolic / endocrine use of LL-37: Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

LL-37 — multifunctional antimicrobial peptide

PMID 16203862

Supporting

Cathelicidin LL-37 in immunity and inflammation

PMID 29503651

LL-37 vs Related Peptides

Compound	Profile	Onset	Best For
LL-37	Cathelicidin antimicrobial peptide	Variable; tissue-localised	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction

Frequently Asked Questions

How does LL-37 affect glycemic control?

LL-37's effect on glycemic markers depends on its primary mechanism. Direct incretin and amylin agonists produce rapid and substantial shifts in fasting glucose and post-prandial response; compounds engaging insulin sensitivity indirectly produce more gradual shifts. Baseline HbA1c and — ideally — a CGM in the first cycle clarifies the individual response.

What metabolic labs should I track?

Baseline panel: fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP, lipoprotein(a), uric acid, urinalysis. Follow-up at 6–8 weeks and 12 weeks. Add waist circumference and — ideally — DEXA or visceral-fat imaging for body-composition tracking.

Is LL-37 appropriate alongside metformin or other diabetes medications?

Most peptide compounds are compatible with metformin and complementary to sulfonylurea or insulin therapy with appropriate dose adjustment. Users on sulfonylureas or insulin should have those doses re-evaluated when adding LL-37 to avoid hypoglycaemia. Metformin combinations are generally well-tolerated and frequently used in metabolic medicine clinics.

Will I regain weight after stopping LL-37?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

What is LL-37?

LL-37 (also known as Cathelicidin LL-37 / Human cationic antimicrobial protein 18) is a 37-residue cathelicidin antimicrobial peptide with a molecular weight of 4493 Da and a plasma half-life of Variable; tissue-localised. Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. The compound is studied primarily in the metabolic / endocrine domain for the applications outlined above.

What is the mechanism of action of LL-37?

Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. For metabolic and glycemic applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. The metabolic / endocrine interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Clinical Protocol

Start a LL-37 Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified LL-37 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 4493 Da
Sequence length: 37 aa
Half-life: Variable; tissue-localised
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

Tesamorelin

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for LL-37 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for LL-37

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised